BioLargo Inc. (OTCQX:BLGO) and its subsidiary Clyra Medical Technologies, Inc. have entered into an exclusive distribution agreement with Al‑Hikma FZCO, a leading healthcare distributor headquartered in Dubai. The deal will allow Al‑Hikma to market and sell Clyra’s ViaCLYR™ wound‑irrigation system throughout the Gulf Cooperation Council, the Levant, North Africa, and select adjacent markets.
The agreement grants Al‑Hikma territorial exclusivity tied to performance metrics, providing Clyra Medical with a dedicated partner to penetrate a region that represents a growing demand for advanced wound‑care solutions. Country‑level regulatory work required for commercial sales across the territory has begun, and Al‑Hikma’s network serves a population of over 500 million people in the Middle East, North Africa, and adjacent regions.
The partnership positions Clyra Medical to tap a growing demand for advanced wound‑care solutions in the MENA region, leveraging Al‑Hikma’s established distribution network. The ViaCLYR™ system, powered by Clyrasept™ Copper‑Iodine Complex Solution, will be the first advanced wound‑care product introduced by Al‑Hikma in the region, providing a strong validation of the technology and a new revenue stream for Clyra.
BioLargo’s broader financial picture shows a decline in revenue to $7.765 million in 2025 from $17.779 million in 2024, and a net loss of $15.189 million in 2025 versus $4.347 million in 2024. The new distribution deal is therefore a critical step toward diversifying revenue streams and offsetting the company’s recent financial challenges.
"Al‑Hikma FZCO is exactly the kind of partner we wanted in this region – established, deeply networked across the Middle East and North Africa, and credible with regulators and the clinical community. Their portfolio strength in wound management makes ViaCLYR™ a natural fit, and with regulatory work already in motion we are well positioned to build commercial momentum," said Steve Harrison, CEO of Clyra Medical Technologies. "This agreement meaningfully expands Clyra’s international footprint and reflects our strategy of partnering with proven, well‑established distributors," added Dennis P. Calvert, Chairman of Clyra Medical Technologies and CEO of BioLargo, Inc. "Al‑Hikma FZCO serves a population of more than 500 million people across some of the most dynamic healthcare markets in the world." Dr. Ali Farooq Abdul‑Qader, Founder and Group CEO of Al‑Hikma FZCO, said, "Clyra’s copper‑iodine technology is differentiated and aligned with our mission to bring innovative, high‑quality healthcare products to the communities we serve. We look forward to a long and productive partnership."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.